The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention

Annual Review of Medicine - Tập 66 Số 1 - Trang 311-328 - 2015
John J. O’Shea1, Daniella M. Schwartz2,1, Alejandro V. Villarino3,1, Massimo Gadina3,1, Iain B. McInnes3,1, Arian Laurence3,1
1Molecular Immunology and Inflammation Branch, National Institute of Arthritis, Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland 20892;
3Molecular Immunology and Inflammation Branch, National Institute of Arthritis,

Tóm tắt

The Janus kinase (JAK)–signal transducer of activators of transcription (STAT) pathway is now recognized as an evolutionarily conserved signaling pathway employed by diverse cytokines, interferons, growth factors, and related molecules. This pathway provides an elegant and remarkably straightforward mechanism whereby extracellular factors control gene expression. It thus serves as a fundamental paradigm for how cells sense environmental cues and interpret these signals to regulate cell growth and differentiation. Genetic mutations and polymorphisms are functionally relevant to a variety of human diseases, especially cancer and immune-related conditions. The clinical relevance of the pathway has been confirmed by the emergence of a new class of therapeutics that targets JAKs.

Từ khóa


Tài liệu tham khảo

10.1056/NEJMra1202117

10.1056/NEJMoa012616

10.1089/hum.2012.116

10.1056/NEJM200301163480314

10.1038/nature06096

10.1056/NEJMoa073687

10.1016/j.immuni.2012.03.016

10.1038/nrd3794

10.1016/j.immuni.2010.05.003

10.1016/j.cell.2012.09.016

10.1038/ni.2025

Mogensen TH., 2013, JAKSTAT, 2, e23435

10.1016/j.immuni.2011.09.016

10.1182/blood-2013-09-523167

10.1016/j.jaci.2012.11.054

10.1016/j.immuni.2006.09.009

10.1016/j.jpeds.2012.01.056

10.1073/pnas.1220098110

10.1146/annurev.immunol.16.1.293

10.4049/jimmunol.177.5.2770

10.1182/blood-2008-05-155770

10.1073/pnas.1003457107

10.1182/blood-2008-03-077966

10.7326/0003-4819-152-5-201003020-00008

10.1038/nsmb.2099

10.1038/nsmb.2348

10.1016/j.clinthera.2011.10.004

10.1080/10428190801895360

10.1002/ajh.22063

10.3324/haematol.2010.033191

10.1182/blood-2007-05-090308

10.1038/ng.2698

10.1038/nrc2734

10.1038/sj.onc.1203483

35. Kryczek I, Lin Y, Nagarsheth N, et al. 2014. IL-22+CD4+ T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity 40:772–84

10.1182/blood-2007-09-111948

10.1056/NEJMoa1114885

10.1182/blood-2012-06-435297

10.1182/blood-2013-04-494930

10.1111/cas.12341

10.1182/blood-2012-12-474577

10.1182/blood-2009-11-255232

10.1038/nri1961

10.1038/cdd.2013.116

10.1016/j.ccr.2010.10.013

10.1111/j.1365-2141.2011.08632.x

10.1016/j.ajhg.2012.02.020

10.1056/NEJMoa073003

10.1093/hmg/11.6.613

10.1038/377065a0

10.1126/science.270.5237.797

10.1016/j.berh.2010.02.003

53. Clark JD, Flanagan ME, Telliez J-B. 2014. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J. Med. Chem. 57:5023–38

10.1046/j.1600-6143.2003.00281.x

10.1002/art.24567

10.1002/acr.20494

10.1002/art.33419

10.1002/art.33383

10.1016/S0140-6736(12)61424-X

10.1002/art.37816

10.1056/NEJMoa1310476

10.1111/j.1600-6143.2012.04127.x

10.1016/j.ophtha.2012.01.028

10.1111/j.1365-2133.2012.11168.x

10.1111/bjd.12517

10.1111/bjd.12266

10.1111/jdv.12081

Menter A, 2014, J. Drugs Dermatol., 13, 252

10.1056/NEJMoa1112168

10.1016/j.cgh.2014.01.029

71. Craiglow BG, King BA. 2014. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J. Invest. Dermatol. 134:2988–90

10.1038/nm.3645

10.1056/NEJMoa1109071

10.1136/ard.2010.139345

10.1056/NEJMoa1112072

Lee EB, 2012, Arthritis Rheum., 64, S1049

10.1186/1471-2474-14-298

78. Winthrop KL, Yamanaka H, Valdez H, et al. 2014. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 66:2675–84

10.3899/jrheum.130683

80. Cohen S, Radominski SC, Gomez-Reino JJ, et al. 2014. Analysis of infections and all-cause mortality in Phase II, III and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 66:2924–37

10.1016/S0735-1097(12)61649-0

10.1111/vde.12088

10.1182/blood.V122.21.108.108

10.1002/art.37857

Tasset C, 2013, Arthritis Rheum., 65, S1018

Vanhoutte F, 2012, Arthritis Rheum., 64, S1051

10.1002/art.38305

10.1073/pnas.1316815111

Thông tin
Thông tin xuất bản

Annual Review of Medicine

Tập 66 Số 1

311-328

Thông tin tác giả